Sensex, Nifty closed on account of Bakri Id; Asian markets rally
NEW DELHI: Indian stock market will remain shut on Monday, 6th October on account of public holiday. The BSE, NSE will remain closed for " Bakri Id".
However, Asian markets were trading higher tracking gains on Wall Street which rose following a stronger-than-expected September U.S. jobs report that bolstered the outlook for the U.S. economy.
"The U.S. Labor Department reported nonfarm payrolls rose 248,000 in September, 33,000 more than median forecast while the jobless rate fell two-tenths of a point to a six-year low of 5.9 percent," Reuters reported.
Tokyo's Nikkei jumped nearly 1 per cent in early trade while South Korean shares rose 0.3 percent after a market holiday on Friday. Hang Seng was trading 0.4 per cent higher.
Back home, Nifty ended the day with a loss of 19 points at 7945 after a range bound session. The BSE Sensex closed 62 points lower at 26567.99 on Wednesday.
Immediate support for Nifty continues to remain at 7920 and if the index manages to respect 7920 as a support and clear the resistance of 8040 as well then we may see further upside till 8090, say analysts.
Markets will closely track data for India's services sector, IIP number and quarterly earnings from IT major Infosys in a holiday-shortened week ahead, say experts.
Important set of data and events are lined in the coming week. To begin with, HSBC Services PMI for August 2014 is due on Tuesday, 7 October 2014. Going ahead, the government will unveil industrial production data for August 2014 on Friday, 10 October 2014.
And lastly, the earning season will also begin from Friday, 10 October 2014 with IT major, Infosys ltd, announcing its Q2 numbers.
"Broadly, the CNX Nifty index has been trading within 7850-8050 for last six trading sessions and either side decisive break will trigger the next directional move," said Jayant Manglik, President-retail distribution, Religare Securities Limited.
"Meanwhile, traders should maintain extra caution and prefer defensive sectors like Pharma, FMCG for short term positions," he added.
Manglik is of the view that investors', on the other hand, should now focus more on stock specific approach before the beginning of earning season and adjust their portfolios accordingly.
Other Latest News
.webp)
AAP supremo Arvind Kejriwal on Thursday intensified his criticism of the BJP-led central government, accusing it of failing to ensure law and order in Delhi.
Addressing a press conference at party office, Kejriwal said, "There is an atmosphere of fear and insecurity everywhere in Delhi. Women feel unsafe stepping out after 7 pm and parents worry about their daughters going outside."
.webp)
The High Court on Thursday refused to ban ISKCON's activities in Bangladesh, a local newspaper reported days after a lawyer was killed in a clash between security personnel and supporters of a Hindu leader arrested on sedition charges.
The lawyer had sought a ban from the high court on the International Society for Krishna Consciousness (ISKCON) after placing some newspaper reports related to the organisation on Wednesday.
.webp)
The Manipur government on Thursday announced that classes in schools and colleges in Imphal Valley districts and Jiribam would resume from November 28 after a hiatus of 13 days.
Educational institutes in these districts have remained closed since November 16 after the dead bodies of three women and three children in Jiribam were recovered from the Jiri and Barak rivers in Manipur and Assam respectively.
.webp)
Eknath Shinde, who served as chief minister in the outgoing Maharashtra government, is unlikely to accept the post of deputy CM in the new dispensation, his close aide Sanjay Shirsat said on Thursday.
Shirsat, an MLA and spokesperson of the Shiv Sena, however, said Shinde would be a part of the cabinet.
.webp)
Dr. Reddy’s announced the launch of Toripalimab in India on Thursday, for patients diagnosed with nasopharyngeal carcinoma (NPC), a rare form of head and neck cancer.
Toripalimab, a New Biological Entity (NBE), is the only immuno-oncology drug approved by regulatory authorities like the USFDA, EMA, and MHRA for treating adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). It is globally recognised for its efficacy in this indication, the Hyderabad-based company said in a statement.
.webp)
.webp)
.webp)
.webp)
.webp)
